Divi's Laboratories Ltd.

NSE: DIVISLAB | BSE: 532488 | ISIN: INE361B01024 | Industry: Pharmaceuticals
| Expensive Performer
6132.5000 32.00 (0.52%)
NSE Aug 14, 2025 15:31 PM
Volume: 407.1K
 

6132.50
0.52%
ICICI Securities Limited
Corporate earnings in Q2FY21 came in better-than-expected wherein companies benefitted from low raw material cost and realised operating leverage benefits with management commentary positive on pace of demand recovery and retaining some part of operating leverage gains in the post Covid world. At the index level, excluding the BFSI space; net sales fell ~10% YoY, primarily driven by double digit topline decline in the oil & gas space. On the profitability front, EBITDA margins at the index level came in at a multi-quarter high at 18.9%, up...
Prabhudas Lilladhar decreased Accumulate price target of Divi's Laboratories Ltd. to 6550.0 on 07 Aug, 2025.
More from Divi's Laboratories Ltd.
Recommended